| Flavivirus Cross-priming Potential of IMOJEV (NCT03920111) | University of Liverpool | 2021-04-16 |
| Seroprevalence of Neutralizing Antibodies Against Japanese Encephalitis Virus Among 6 Years Old Children With 5 Different Immunization Strategies in Zhejiang Province (NCT04817917) | Zhejiang Provincial Center for Disease Control and Prevention | 2021-03-01 |
| Evaluate Safety and Immunogenicity of a Vero Cell-Derived JE Vaccine in 9-24 Months of Age Children in Vietnam (NCT03282370) | National Institute of Hygiene and Epidemiology, Vietnam | 2017-09-30 |
| Safety of Vero Cell - Derived Inactivated Japanese Encephalitis Vaccine (JECEVAX) in Children From 9-24 Months of Age (NCT03204227) | National Institute of Hygiene and Epidemiology, Vietnam | 2017-06-02 |
| Postmarketing Surveillance Study for IMOJEV® in Republic of Korea (NCT02933710) | Sanofi Pasteur, a Sanofi Company | 2016-07-21 |
| Immunogenicity of Co-administration of Measles and Japanese Encephalitis Vaccines (NCT02643433) | Centers for Disease Control and Prevention, China | 2015-08-01 |
| Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj (NCT02532569) | Boryung Pharmaceutical Co., Ltd | 2015-08-01 |
| Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV®) in Healthy Subjects (NCT02492165) | Sanofi Pasteur, a Sanofi Company | 2015-06-01 |
| Safety and Immunogenicity of JECEVAX in Young Children (NCT02816554) | National Institute of Hygiene and Epidemiology, Vietnam | 2015-04-01 |
| Immunogenicity of a JE-CV as a Booster Dose After a Primary Vaccination With SA14-14-2 Vaccine (NCT02602652) | Chulalongkorn University | 2013-12-01 |
| Antibody Response of a Boosted Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children (NCT01954810) | Khon Kaen University | 2013-10-01 |
| Study of a Booster Dose of IMOJEV® One Year After Primary Immunization in Healthy Children in South Korea (NCT01900444) | Sanofi Pasteur, a Sanofi Company | 2013-07-11 |
| Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE Vaccine (NCT01815073) | Changchun Keygen Biological Products Co., Ltd. | 2013-03-01 |
| Safety and Immunogenicity of 2 Different Vaccination Schedules of Rabies and Japanese Encephalitis Vaccines in Healthy Adult Subjects (NCT01662440) | Novartis Vaccines | 2012-08-01 |
| Immune Response in IXIARO Batch JEV09L37 Recipients Before and After Revaccination (NCT01559831) | Valneva Austria GmbH | 2012-06-01 |
| A Prospective, Open Label Study of Human T Cell Responses to Live Attenuated Japanese Encephalitis Vaccine SA14-14-2 (NCT01656200) | Indian Institute of Science | 2012-05-01 |
| Lot-to-lot Consistency Trial of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine (NCT01567865) | PATH | 2012-05-01 |
| A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults (NCT01466387) | Novartis | 2011-11-01 |
| Study of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV™) Compared to CD.JEVAX™ in Toddlers (NCT01396512) | Sanofi Pasteur, a Sanofi Company | 2011-07-01 |
| Safety Surveillance After Immunization With IXIARO (NCT01335412) | Valneva Austria GmbH | 2011-03-01 |
| Open-label, Randomized Study in a Pediatric Population in a JEV (Japanese Encephalitis Virus)-Endemic Country (NCT01296360) | Valneva Austria GmbH | 2010-12-01 |
| Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study (NCT01246479) | Valneva Austria GmbH | 2010-10-01 |
| Study of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Children Previously Immunized With JE-CV (NCT01190228) | Sanofi Pasteur, a Sanofi Company | 2010-08-25 |
| Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers (NCT01188343) | Sanofi Pasteur, a Sanofi Company | 2010-08-01 |
| This is a Study to Assess the Safety and Immunogenicity of Ixiaro® (IC51) in an Elderly Population (NCT01158599) | Valneva Austria GmbH | 2010-06-01 |
| A Study of Japanese Encephalitis Chimeric Virus Vaccine Compared With SA14-14-2 Vaccine in Infants and Toddlers (NCT01092507) | Sanofi Pasteur, a Sanofi Company | 2010-03-01 |
| Long-term Follow-up of Immunogenicity of a Single Dose of Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) in Toddlers (NCT01001988) | Sanofi Pasteur, a Sanofi Company | 2009-08-07 |
| Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR (NCT00938379) | London School of Hygiene and Tropical Medicine | 2009-07-01 |
| Safety and Efficacy Study of Intravenous Immunoglobulin to Treat Japanese Encephalitis (NCT01856205) | University of Liverpool | 2009-05-01 |
| Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling (NCT00776230) | Valneva Austria GmbH | 2008-09-01 |
| Study of ChimeriVax™-Japanese Encephalitis Vaccine in Toddlers in Thailand and the Philippines (NCT00735644) | Sanofi Pasteur, a Sanofi Company | 2008-08-01 |
| Immunogenicity and Safety of ChimeriVax™ Japanese Encephalitis Vaccine in Thai Toddlers and Children (NCT00621764) | Sanofi Pasteur, a Sanofi Company | 2008-03-01 |
| Ixiaro as Booster After Mouse-brain Derived Vaccines for Japanese Encephalitis (NCT01386827) | Helsinki University Central Hospital | 2008-01-01 |
| Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 (NCT00595309) | Valneva Austria GmbH | 2007-12-01 |
| Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51 (NCT00595465) | Valneva Austria GmbH | 2007-12-01 |
| Boosterability of Live Attenuated Japanese Encephalitis (JE) Vaccine in Children Who Have Previously Received Inactivated JE Vaccine (NCT00463476) | PATH | 2007-07-09 |
| Live Attenuated Japanese Encephalitis (JE) Vaccine Coadministered With Measles Vaccine in Infants 9 Months of Age (NCT00463684) | PATH | 2007-07-07 |
| A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVax™-JE and JE-VAX (NCT00314145) | Sanofi | 2005-11-01 |
| Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. (NCT00314132) | Sanofi | 2005-10-01 |
| Long Term Persistence and Effect of a Booster Dose of the Japanese Encephalitis Vaccine IC51 (NCT00595270) | Valneva Austria GmbH | 2005-10-01 |
| Longterm Immunogenicity of the Japanese Encephalitis Vaccine IC51 (NCT00596102) | Valneva Austria GmbH | 2005-10-01 |
| Safety and Tolerability of the Japanese Encephalitis Vaccine IC51 (NCT00605085) | Valneva Austria GmbH | 2005-10-01 |
| Concomitant Vaccination With the Japanese Encephalitis Vaccine IC51 and HARVIX® 1440 (NCT00596271) | Valneva Austria GmbH | 2005-09-01 |
| Immunogenicity Study of the Japanese Encephalitis Vaccine IC51 (NCT00604708) | Valneva Austria GmbH | 2005-09-01 |
| Treatment of Japanese Encephalitis (NCT00216268) | Indian Council of Medical Research | 2005-07-01 |
| A Safety and Efficacy Study of Two Japanese Encephalitis Vaccines ChimeriVaxTM-JE and JE-VAX (NCT00319592) | Sanofi | 2005-05-01 |
| Study of Live Attenuated ChimeriVax™-Japanese Encephalitis Vaccine (NCT00981630) | Sanofi | 2004-11-01 |
| Study of Live Attenuated Japanese Encephalitis Vaccine (ChimeriVax™-JE) and Yellow Fever Vaccine (STAMARIL®) (NCT00982137) | Sanofi | 2004-07-01 |
| A Study of ChimeriVax™-JE Live Attenuated Vaccine in Healthy Adults (NCT00981175) | Sanofi | 2003-04-01 |
| Evalution of Immunogenicity, Safety and Booster Response of a Rabies Vaccine Administered Concomitantly With Japanese Encephalitis Vaccine in Toddlers (NCT00694460) | Novartis | 2002-08-01 |